BUTOCTAMIDE SEMISUCCINATE

Possibly Marketed Outside US

Details

Stereochemistry	MIXED
Molecular Formula	C16H29NO5
Molecular Weight	315.4052
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC(CC)CNC(=O)CC(C)OC(=O)CCC(O)=O

InChI

InChIKey=CQONVBIGUJWUFE-UHFFFAOYSA-N

InChI=1S/C16H29NO5/c1-4-6-7-13(5-2)11-17-14(18)10-12(3)22-16(21)9-8-15(19)20/h12-13H,4-11H2,1-3H3,(H,17,18)(H,19,20)

HIDE SMILES / InChI

Molecular Formula	C16H29NO5
Molecular Weight	315.4052
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7624490
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/7604145 and http://www.ncbi.nlm.nih.gov/pubmed/6813899

Butoctamide (Butoctamide hydrogen succinate, BAHS), which is related to an organic compound naturally occurring in CSF, has been demonstrated to increase REM sleep in cats and young adults. BAHS was confirmed also to increase REM sleep in healthy aged subjects. The drug is marketed under the brand named Listomin S in Japan. It is effective against insomnia and other sleep disorders.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
serotonin secretion 8 Target ID: GO:0001820 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6813899	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 111 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7624490	Primary		Approved 8583	Listomin Approved Use Hypnotics and sedatives

Doses

Dose	Population	Adverse events
1000 mg single, oral Studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2497487/	healthy Health Status: healthy Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2497487/	Sources: https://pubmed.ncbi.nlm.nih.gov/2497487/
400 mg 1 times / day multiple, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7604145/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7604145/	Sources: https://pubmed.ncbi.nlm.nih.gov/7604145/

PubMed

Title	Date	PubMed
Release of serotonin from mast cells induced by N-(2-ethylhexyl)-3-hydroxybutyramide and catecholamine.	1977-02-01	66055

Patents

Sample Use Guides

In Vivo Use Guide

three capsules (600mg) at night

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:30:12 GMT 2025` Edited by `admin` on `Mon Mar 31 19:30:12 GMT 2025`
Record UNII	F58251NT6M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUTOCTAMIDE SEMISUCCINATE

Common Name

English

BUTOCTAMIDE SUCCINATE

Preferred Name

English

BUTOCTAMIDE HEMISUCCINATE

Common Name

English

BUTOCTAMIDE SEMISUCCINATE [JAN]

Common Name

English

Butoctamide succinate [WHO-DD]

Common Name

English

BUTOCTAMIDE HYDROGEN SUCCINATE [MI]

Common Name

English

BUTANEDIOIC ACID, 1-(3-((2-ETHYLHEXYL)AMINO)-1-METHYL-3-OXOPROPYL) ESTER

Common Name

English

Code System Code Type Description

ChEMBL

CHEMBL452859